anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing Coptidis Rhizoma extract for preventing and treating respiratory disease is provided to ensure high anti-histamine activity and discharge of phlegm. CONSTITUTION: A composition for discharge of phlegm contains Coptidis Rhizoma extract as an active ingredient. The Coptidis Rhizoma extract is crude extract or polar solvent soluble extract of crude extract. The crude extract is extract using water, straight or branched alcohol of 1-6 carbon atoms or their mixture solvent. The Coptidis Rhizoma extract contains berberine, palmatine, coptisine, and jatrorhizine. The composition is used in the form of powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, suppository or sterilization injection solution.
PURPOSE:To obtain a dental magnetic alloy with a low m.p. and superior castability by adding Pd and Si to Co or Ni in a specified ratio. CONSTITUTION:This dental magnetic alloy consists of, by wt. 28-75% Pd, <=5% Si and 20-70% Co or Ni. The restricted Co or Ni content adjusts the melting temp. of the alloy to <=1,350 deg.C, and Co or Ni alloyed with Pd provides high corrosion resistance. Si has the effect of improving the castability and reducing blow holes. By this composition the casting timing is easily judged.
Super refractory status epilepticus (SRSE) is a condition associated with high rates of mortality and morbidity. We report the treatment protocol of magnesium sulphate infusion adapted for the management of a case of super refractory status epilepticus that lasted for 4 weeks. A young lady presented in altered sensorium with a history of fever followed by uncontrolled seizures of 2 weeks duration. Her serum tested weakly positive for GABA-B receptor antibody. Her seizures were not controlled despite being on multiple antiepileptics and anesthetic induction. Intravenous magnesium infusion was initiated and serum magnesium was titrated up to a final target concentration of 3.8-6.5 mg/dl. Seizure control was achieved after 11 days of the infusion. This case is the longest reported successful use of magnesium sulfate infusion for control of super refractory status epileptics.
Objective: Uterine-sparing surgery for pelvic organ prolapse (POP) repair has shown good results, but the potential negative implications of leaving the uterus in place are yet to be fully defined. We aimed to assess the risk of unanticipated abnormal gynecological pathology at the time of reconstructive pelvic surgery. Methods: A retrospective consecutive case series including women who underwent vaginal hysterectomy for POP repair at a tertiary medical center in 2006-2020. All patients were offered a free Pap smear test at the age of 65 years as part of a national screening program. Transvaginal ultrasound was routinely performed preoperatively. Standard 3 pedicle hysterectomy was performed with/without bilateral salpingo-oophorectomy (BSO). Results: The study comprised 462 women of mean age 63 ± 9.3 years without previous known malignant or premalignant pathology. Benign pathology was observed in 286 patients (61.9%). Endometrial malignancy was found in three patients (0.7%) and significant premalignant pathology in 15 patients (3.2%), including cervical intraepithelial neoplasia stage 2-3 in seven patients (1.5%) and complex hyperplasia with atypia in eight patients (1.7%). All these pathologies were found in postmenopausal women. None had preoperative clinical symptoms or endometrial thickness of ≥5 mm on preoperative ultrasound. In the 35 patients after BSO, adnexal findings were normal (77.2%) or benign (22.8%). Conclusions: Premenopausal women with uterovaginal prolapse and normal preoperative evaluation have a minimal risk of significant abnormal uterine pathology. In postmenopausal women, the risk of unanticipated malignant uterine pathology is 0.7% and 3.2% for significant premalignancy.
PURPOSE: To obtain a cosmetic having high whitening action, inhibiting activity of hyaluronidase, having excellent lubricating and flexibility-making action to skin and preventing irritations or senescence of skin. CONSTITUTION: This cosmetic contains a solvent extract of a plant body selected from edible plant whose safety is confirmed such as jatoba, jequirtiba, puca, veronica and casca-doce as an essential component. A seed and a back as the plant body or jatoba, a back as the plant body of jequitiba, a seed as the plant body of puca and a back as the plant of veronica and casca-doce are especially effectively used. The extraction is performed by using water or a hydrophilic organic solvent (e.g. ethanol). Other the extract, a liquid oil, a solid oil, various activating agents, a wetness-keeping agent and various medicines are suitably mixed and prepared to a lotion, a cream, a latex or a pack, etc.
A treatment device may comprise a cover defining a cavity, wherein the cavity is configured to receive a part of a body. The cover may comprise at least one sheet having a composite structure. The composite structure may comprise at least two layers and at least one adhesive matrix situated between the two layers. At least one of the two layers may be permeable to a solvent, and the two layers may be permanently bonded to the adhesive matrix. The adhesive matrix may contain at least one active agent that is soluble in the solvent. When the active agent is dissolved in the solvent, the active agent may be released from at least one side of the cover.
In Uzbekistan, NCDs, including cardiovascular diseases, cancer, and diabetes, accounted for over 80% of mortality in 2019. In 2021, national stakeholders, in conjunction with the World Health Organization, identified brief interventions (BIs) to implement in primary health care settings to change unhealthy behaviors and reduce the burden of NCDs in the country. BIs consist of a validated set of questions to identify and measure NCD behavioral risk factors and a short conversation with patients/clients about their behavior, as well as the provision of a referral opportunity for further in-depth counseling or treatment if needed. We used a multimethod approach of document review, participatory workshops, and key informant interviews to describe how BIs were designed and implemented in Uzbekistan and generated a theory of change for its large-scale implementation. BIs in Uzbekistan targeted 4 risk factors (alcohol use, tobacco use, unhealthy diet, and physical inactivity) and entailed training clinicians on how to conduct behavioral change counseling using the 5As and 5Rs toolkit, conducting supportive supervision, and using feedback to improve service delivery. The program was collaboratively designed by multiple stakeholders across sectors, including the Ministries of Health, Higher Education, Science, and Innovations, with buy-in from key political leaders. The potential impact of the program (i.e., reducing the incidence of NCDs) was mediated by several intermediate and implementation outcomes at the individual, primary care, and community levels operating along multiple pathways. Significant health system challenges remain to the program, such as limited human resources, lack of incentives for clinicians, outdated systems and data collection processes for performance monitoring, and coordination among different relevant sectors. These and other challenges will need to be addressed to ensure the effective large-scale implementation of BIs in Uzbekistan and similar LMICs.
Seventy-one nursery school teachers working in nine school buildings were randomly divided into two groups, with each school as a unit of randomization. All the teachers in both groups received an ergonomic brochure; teachers in the experimental group also received an extension-oriented exercise program, conducted by a physical therapist. Data were collected at baseline and at a two-month follow-up. The primary outcome measure recorded was the level of disability (Roland Morris Disability Questionnaire and Oswestry Disability Index), while secondary outcome measures included LBP and neck pain presence (Pain Drawing) and intensity (Visual Analogue Scale). At follow-up, a significant improvement was registered in the experimental group for all the outcomes evaluated. In conclusion a six-session extension-oriented exercise program proved decisive in preventing low back and neck complaints and in reducing consequent LBP functional disability among nursery school teachers.
1. Use of a TNF antagonist which is the TNF antagonists or a TNF receptor signaling as an active carrier of a pharmaceutical composition for the treatment and/or prevention of endometriosis. 2. The use of the TNF antagonist which is the TNF antagonists or a TNF receptor signaling as an active carrier of a pharmaceutical composition to improve the implantation and fertility rate by reducing endometriotic lesions. 3. The use of Claim 1 or 2 wherein the TNF antagonist is a receptor molecule, derivative or a fragment thereof which binds to TNF. 4. The use of Claim 3 wherein the receptor molecule is selected from the group consisting of: TNF-RI and TNF-RII. 5. The use of Claim 3 wherein the receptor molecule is the extracellular domain of TNF-RI. 6. The use of Claim 3 wherein the receptor molecule is human soluble recombinant TNF-RI. 7. The use of Claim 3 wherein the receptor molecule is a TNF receptor multimeric molecule or a functional portion thereof. 8. The use of Claim 7 wherein the TNF receptor multimeric molecule comprises all or a functional portion of two or more extracellular domains of TNF receptors linked via one or more polypeptide linkers. 9. The use of Claim 3 wherein the receptor molecule is an immunoreceptor fusion molecule or a functional portion thereof. 10. The use of Claim 9 wherein the immunoreceptor fusion molecule comprises all or a functional portion of TNF receptor and an immunoglobulin chain. 11. The use of Claim 1 or 2 wherein the TNF antagonist is an anti-TNF antibody or a fragment thereof. 12. The use of Claim 11 wherein the monoclonal antibody is selected from the group consisting of: a chimeric monoclonal antibody, a humanized monoclonal antibody or fragment thereof. 13. The use of Claim 1 in which the TNF antagonist prevents or inhibits TNF receptor signaling. 14. A method for treating and/or preventing endometriosis which comprises administering to a patient a therapeutically effective dose of a TNF antagonist. 15. Pharmaceutical composition containing a TNF antagonist, together with a pharmaceutically acceptable carrier, in the treatment and/or prevention of endometriosis. 16. Pharmaceutical composition containing a TNF antagonist, together with a pharmaceutically acceptable carrier, in the treatment and/or prevention of endometriosis-related infertility. 17. The pharmaceutical composition according to Claim 15 or 16 wherein the TNF antagonist has the features set out in any one of Claims 1 to 13.
AIMS: Sudden cardiac death (SCD) is a serious consequence of a myocardial infarction (MI), but identifying patients at risk of developing SCD remains a major clinical challenge, especially in the case of juvenile MI. The aim of this study is to identify predictors of SCD after early-onset MI using long-term follow-up data relating to a large nationwide patient cohort.
METHODS AND RESULTS: The Italian Genetic Study on Early-onset MI enrolled 2000 patients experiencing a first MI before the age of 45 years, who were followed up for a median of 19.9 years. Fine-Gray proportional hazard models were used to assess the associations between their clinical, demographic, and index event data and the occurrence of SCD. Sudden cardiac death occurred in 195 patients, who were more frequently males, were hypertensive and/or diabetic, had a history of previous thrombo-embolic events with a greater atherosclerotic burden, and had a lower left ventricular ejection fraction (LVEF) after the index event. A multivariable analysis showed that the independent predictors of SCD were diabetes, hypertension, previous thrombo-embolic events, a higher SYNTAX score, and a lower LVEF. There was no clear evidence of the clustering of SCD events during the follow-up. Sudden cardiac death was the first post-MI clinical event in 101 patients; the remaining 94 experienced SCD after a non-fatal MI or hospitalization for coronary revascularization.
CONCLUSION: Sudden cardiac death frequently occurs during the 20 years after early-onset MI. The nature of the identified predictors and the absence of clustering suggest that the pathophysiological basis of SCD may be related to progressive coronary atherosclerosis.
BACKGROUND: Iatrogenic pseudoaneurysms arising from the internal carotid artery subsequent to carotid endarterectomy are exceptionally infrequent. Herein, we present a case detailing an internal carotid artery pseudoaneurysm that manifested subsequent to a hybrid carotid endarterectomy and endovascular therapy intervention. Our approach to managing this condition involved a novel technique wherein thrombin was directly injected into the luminal cavity of the pseudoaneurysm under the guidance of a C-arm.
CASE PRESENTATION: A 66-year-old male patient of Chinese ethnicity exhibited a 4-month history of headache and a 20-day history of gait disturbance. Digital subtraction angiography revealed occlusion in the cervical region of the left carotid artery. Following a hybrid surgical procedure, the patient reported mild pain and bruising surrounding the incision site of the left internal carotid artery endarterectomy. Subsequent angiography identified the presence of a carotid artery pseudoaneurysm. Utilizing C-arm guidance, thrombin was then directly injected into the luminal cavity of the pseudoaneurysm, resulting in complete healing during follow-up.
CONCLUSION: For the management of pseudoaneurysms arising post carotid endarterectomy, the direct injection of thrombin into the aneurysm cavity under the guidance of a C-arm is deemed both safe and efficacious.
The present invention discloses an iron replenisher of slow release control type iron and a preparation method and a purpose thereof. The iron replenisher is zeolite containing active iron, and the content of iron in the zeolite is 1.5% to 10% according to the percentage by weight. In the preparation method, zeolite containing active iron is prepared by the procedures of the adsorption and the ion exchange reaction between a divalent molysite and natural artificially synthesized zeolite, filtering, drying and pulverizing. The preparation method has the advantages of simple technological process, low production cost and easy popularization and implementation. Because carrier zeolite has the characteristics of good biocompatibility and gastrointestinal tract mucosa compatibility, regular intercommunicating pore canal structure and cage space, high surface activity, large specific surface area, etc., iron carried by the carrier zeolite has a slow release control function, and the absorption and the utilization rate of iron is greatly raised. The slow release control type iron prepared by the present invention can be used as a feed additive applied to iron replenishment for fowls, aquatic livestock, cattle, sheep, etc., and can be also used for preparing human oral taking iron replenishment health products or medicines for treating human diseases by administration of remedial iron. The slow release control type iron has wide application range.
This retrospective study endeavors to scrutinize risk factors associated with infections resulting from external ventricular drainage (EVD) and to assess the effectiveness of chlorhexidine dressing in mitigating infection rates. Conducted from January 2018 to July 2023, this single-center study encompassed 108 EVD patients. Comprehensive data on demographics, comorbidities, surgical procedures, and the utilization of chlorhexidine dressing were meticulously compiled. The primary endpoint was the incidence of EVD-associated infections based on CDC criteria. Infection rates attributable to EVD were 24.32% without and 20.59% with chlorhexidine dressing. Notably, diabetes mellitus emerged as the solitary significant infection risk factor (p < 0.01). Although the application of chlorhexidine dressing suggested a propensity for diminishing infection rates, statistical significance remained elusive. No notable disparities were discerned in variables such as catheter type, procedural location, and underlying diseases. Diabetes mellitus has been identified as a significant risk factor for EVD-associated infections. While the utilization of chlorhexidine dressing exhibited a potential reduction in infection rates, the lack of statistical significance underscores the imperative for further research, encompassing more expansive randomized trials, to comprehensively evaluate the safety and efficacy of chlorhexidine dressings in preventing EVD-associated infections.
<P>PROBLEM TO BE SOLVED: To provide a substantially purified GDF (growth differentiation factor) receptor including a GDF-8 (myostatin) receptor, as well as a functional peptide portion thereof.  <P>SOLUTION: A virtual representation of the GDF receptor or the functional peptide portion thereof is provided. A method for modulating an effect of myostatin on a cell by bringing the cell into contact with an agent that affects myostatin signal transduction in the cell is provided. A method for ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development, or metabolic activity of muscle or adipose tissue in a subject, by modulating the myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject is provided. A method for modulating the growth of muscle tissue or adipose tissue in a eukaryotic organism by administering an agent that affects the myostatin signal transduction to the organism is provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
It is possible to radiosensitize tumor cells by administration of compositions containing the Human antisense c-raf-1 oligodeoxyribonucleotide (ODN/oligo) sequence: 5′-GTGCTCCATTGATGC-3′ (seq. ID No. 1) wherein only the end bases are phosphorylated is a preferred embodiment. Antisense sequences of up to 40 bases which containing this sequence may be used in accord with the teachings of this disclosure. Compositions comprising a cationic liposome of dimethyldioctadecyl ammonium bromide, phosphatidylcholine and cholesterol may be used as a carrier system. The liposomes provide a new carrier system that is particularly useful for administration of sequences for therapy.
Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.
The present invention relates to methods of treating or preventing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a subject, which comprises administering to the subject a therapeutically or prophylactically effective amount of an agent which is a protein comprising amino acids 19 to 168 of the amino acid sequence in FIG.  2  (SEQ ID NO: 2) or a functional equivalent of this protein. Said protein of FIG.  2  of the present application has been designated in the prior art as Coversin, Nomacopan, EV576 or OmCI protein. Alternatively the agent is a nucleic acid molecule encoding a protein comprising amino acids 19 to 168 of the amino acid sequence in FIG.  2  (SEQ ID NO: 2) or a functional equivalent of this protein.
Alzheimer's disease (AD) is the most common cause of dementia. A genome-wide association study has shown that several AD risk genes are involved in lipid metabolism. Additionally, epidemiological studies have indicated that the levels of several lipid species are altered in the AD brain. Therefore, lipid metabolism is likely changed in the AD brain, and these alterations might be associated with an exacerbation of AD pathology. Oligodendrocytes are glial cells that produce the myelin sheath, which is a lipid-rich insulator. Dysfunctions of the myelin sheath have been linked to white matter abnormalities observed in the AD brain. Here, we review the lipid composition and metabolism in the brain and myelin and the association between lipidic alterations and AD pathology. We also present the abnormalities in oligodendrocyte lineage cells and white matter observed in AD. Additionally, we discuss metabolic disorders, including obesity, as AD risk factors and the effects of obesity and dietary intake of lipids on the brain.
Participants assigned to 1 of 3 dose-escalation cohorts will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.
As the population ages in China, the number of patients with neurocognitive disorders such as Alzheimer's disease (AD) and vascular cognitive impairment (VCI) is steadily increasing. The burden of cognitive impairment in China has been an important public health problem. Cohort study on aging and cognitive impairment is urgent to better understand and address this issue. Early prevention, diagnosis and treatment are critical for reduction the burden of cognitive impairment. In this prospective study, subjects will be recruited into one of the five groups based on inclusion and exclusion criteria: 1) CN, 2) MCI 3) AD and 4) VCI. Each of the subjects will be followed up at designated time points up to 5 years. Epidemiological data, medical, imaging (MRI and PET scans), genetic information and various biological samples will be collected during the baseline and follow-up period.
This is a behavioral control where no change in Vitamin D status is expected to occur. Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily for 12 weeks.
Pyroptosis, a novel programmed cell death mediated by NOD-like receptor protein 3 (NLRP3) inflammasome, is a critical pathogenic process in acute viral myocarditis (AVMC). Mitsugumin 53 (MG53) is predominantly expressed in myocardial tissues and has been reported to exert cardioprotective effects through multiple pathways. Herein, we aimed to investigate the biological function of MG53 in AVMC and its underlying regulatory mechanism in pyroptosis. BALB/c mice and HL-1 cells were infected with Coxsackievirus B3 (CVB3) to establish animal and cellular models of AVMC. As inflammation progressed in the myocardium, we found a progressive decrease in myocardial MG53 expression, accompanied by a significant enhancement of cardiomyocyte pyroptosis. MG53 overexpression significantly alleviated myocardial inflammation, apoptosis, fibrosis, and mitochondrial damage, thereby improving cardiac dysfunction in AVMC mice. Moreover, MG53 overexpression inhibited NLRP3 inflammasome-mediated pyroptosis, reduced pro-inflammatory cytokines (IL-1β/18) release, and suppressed NF-κB signaling pathway activation both in vivo and in vitro. Conversely, MG53 knockdown reduced cell viability, facilitated cell pyroptosis, and increased pro-inflammatory cytokines release in CVB3-infected HL-1 cells by promoting NF-κB activation. These effects were partially reversed by applying the NF-κB inhibitor BAY 11-7082. In conclusion, our results suggest that MG53 acts as a negative regulator of NLRP3 inflammasome-mediated pyroptosis in CVB3-induced AVMC, partially by inhibiting the NF-κB signaling pathway. MG53 is a promising candidate for clinical applications in AVMC treatment.